Cancer clinical trials in the region Pays de la Loire
433 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Acute leukemia
#NCT07007312
#2025-521314-25-00
Etude de thérapie non intensive
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
12 recruiting sites
Kura Oncologie, Inc.
Phase 3
Penile cancer and germ cell tumors
#NCT05874063
#2022-502426-41-00
Required histologic types
Germ cell tumor
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required IGCCCG prognostic scores
Good prognosis
Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lung cancer
#NCT07099898
#2025-521627-78
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
3 recruiting sites
GlaxoSmithKline
Phase 3
Head and neck cancer
#NCT06525220
#2023-510323-30-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
14 recruiting sites
Merus
Phase 3
Breast cancer
#NCT07237256
#2025-520979-13-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Excluded previous treatments at localized stage
Chemotherapy
Targeted therapy
17 recruiting sites
UNICANCER
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06545955
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Surgery
Immunotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
9 recruiting sites
Ferring Pharmaceuticals
Phase 3
Lymphoma
#NCT06717347
#2024-515566-13-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
14 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06868277
#2024-517780-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
11 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT07205822
#2025-521904-23-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
5 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06472245
#2023-509340-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded genetic anomalies
ALK
EGFR
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
29 recruiting sites
OSE Immunotherapeutics